PTSD is the flagship indication for MDMA-assisted therapy, which has completed Phase III trials and remains the most advanced psychedelic treatment program in the United States. Research also extends to psilocybin and ibogaine for trauma-related symptoms, including studies in veterans and first responders. This directory tracks every PTSD and trauma-related psychedelic study on ClinicalTrials.gov.
| Trial | Drug | Phase | Status | Sponsor | Conditions | Start date |
|---|---|---|---|---|---|---|
| Psilocybin After Trauma Surgery for Pain | Psilocybin | Phase 1 | Not Yet Recruiting | Trent Emerick | Pain Management, Postoperative Pain | Dec 31, 2027 |
| MDMA-AT for PTSD in Young Adults With Childhood Trauma | MDMA | Phase 2 | Not Yet Recruiting | Jenna M. Traynor | Posttraumatic Stress Disorder (PTSD) | Oct 31, 2026 |
| MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders | MDMA | Phase 2 | Not Yet Recruiting | Nautilus Sanctuary | Post-Traumatic Stress Disorder, Adjustment Disorders | Oct 1, 2026 |
| Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | Multiple | Phase 2 / Phase 3 | Recruiting | COMPASS Pathways | PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms, PTSD, Post Traumatic Stress Disorder | Sep 1, 2026 |
| Psilocybin-Assisted Therapy for Intergenerational Trauma | Psilocybin | Phase 2 | Recruiting | Rachel Yehuda | Psychological Stress, Depression, Anxiety | Aug 28, 2026 |
| Mindfulness-based Psilocybin Therapy for PTSD | Psilocybin | Phase 2 | Recruiting | Anthony P King | Post Traumatic Stress Disorder, Depression - Major Depressive Disorder | Jul 1, 2026 |
| MDMA-Assisted Massed Exposure Therapy for PTSD | MDMA | Phase 2 | Recruiting | Emory University | Post Traumatic Stress Disorder | Jul 1, 2026 |
| MDMA Therapy in Veterans With PTSD | MDMA | Phase 2 | Recruiting | Sunstone Medical | Post Traumatic Stress Disorder | Jun 30, 2026 |
| Psilocybin-Assisted Therapy | Psilocybin | Phase 2 | Recruiting | Emory University | PTSD | Jun 8, 2026 |
| Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD | Psilocybin | Phase 2 | Recruiting | Sunstone Medical | Post Traumatic Stress Disorder, PTSD | May 23, 2026 |
| MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder | MDMA | Phase 2 / Phase 3 | Recruiting | VA Office of Research and Development | Post Traumatic Stress Disorder, Alcohol Use Disorder | May 18, 2026 |
| Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder | Psilocybin | Phase 1 | Recruiting | University of New Mexico | PTSD | May 1, 2026 |
| Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD | Psilocybin | Phase 1 | Active Not Recruiting | Scottsdale Research Institute | PTSD | Mar 20, 2026 |
| Integrated PTSD and Chronic Pain Treatment | Psilocybin | N/A | Recruiting | Weill Medical College of Cornell University | PTSD, Chronic Pain | Dec 8, 2025 |
| Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD) | Multiple | Phase 1 | Recruiting | Johns Hopkins University | Posttraumatic Stress Disorder | Sep 17, 2025 |
| Trifecta Research Study | Multiple | Phase 2 | Withdrawn | Johns Hopkins University | PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Trauma, Brain Injuries | Sep 1, 2025 |
| MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents | MDMA | Phase 2 | Withdrawn | University of California, Los Angeles | PTSD, Post Traumatic Stress Disorder, Adolescents, Psychotherapy | Jul 1, 2025 |
| Dose Optimization of MDMA-Assisted Therapy for PTSD | MDMA | Phase 2 | Recruiting | Bronx VA Medical Center | Posttraumatic Stress Disorder | Jun 3, 2025 |
| Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD) | Psilocybin | Phase 2 | Active Not Recruiting | Nathan Brashares Sackett | Alcohol Use Disorder (AUD), PTSD | Jun 1, 2025 |
| MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder | MDMA | Phase 2 | Recruiting | Stephen Robert Marder | Post Traumatic Stress Disorder | Mar 1, 2025 |
| MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder | MDMA | Phase 2 | Recruiting | Patricia Suppes | PTSD | Feb 10, 2025 |
| State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma | Psilocybin | Phase 2 | Recruiting | Baylor College of Medicine | PTSD | Jan 30, 2025 |
| Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics | Multiple | N/A | Terminated | Yale University | OCD, Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Healthy Volunteer, Migraine, PTSD, PTSD - Post Traumatic Stress Disorder, Addiction, Tobacco Use Disorder, Obsessive Compulsive Disorder (OCD), Opioid Use Disorder | Dec 12, 2024 |
| MDMA-assisted Massed Prolonged Exposure for PTSD | MDMA | Phase 3 | Active Not Recruiting | Healing Breakthrough | Post-Traumatic Stress Disorder | Oct 25, 2024 |
| Open-Label Psilocybin Study in Transdiagnostic Population | Psilocybin | Phase 1 | Recruiting | Yale University | Transdiagnostic, Depression - Major Depressive Disorder, Anxiety, PTSD Symptoms, PTSD, Substance Use, Substance Use Disorder (SUD), OCD | Oct 17, 2024 |
| A Study of Psilocybin for PTSD | Psilocybin | Phase 1 | Active Not Recruiting | Johns Hopkins University | Post Traumatic Stress Disorder | Jun 7, 2024 |
| Mindful Self-Compassion to Address PTSD and Substance Use in Unhoused Women | Psilocybin | N/A | Completed | University of California, Los Angeles | Posttraumatic Stress Disorder (PTSD), Anxiety, Depression - Major Depressive Disorder | May 5, 2024 |
| The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD. | MDMA | Phase 1 | Withdrawn | Yale University | Post Traumatic Stress Disorder | May 1, 2024 |
| MDMA for Co-occurring PTSD and OUD After Childbirth | Multiple | Phase 2 | Recruiting | University of New Mexico | Stress Disorders, Post-Traumatic, Opioid Use Disorder | Apr 16, 2024 |
| MDMA Plus Exposure Therapy for PTSD | MDMA | Phase 2 | Enrolling By Invitation | Emory University | PTSD | Feb 13, 2024 |
| MDMA for AUD/PTSD Comorbidity | MDMA | Phase 2 | Completed | Carolina L Haass-Koffler | Alcohol Use Disorder, Post Traumatic Stress Disorder | Feb 6, 2024 |
| MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD | MDMA | Phase 3 | Completed | Dr. Leslie Morland | PTSD, Relational Problems | Oct 6, 2023 |
| Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults | DMT | Phase 1 | Unknown | Advanced Integrative Medical Science Institute | Major Depression, Post Traumatic Stress Disorder | Oct 1, 2023 |
| Group MDMA-therapy for Veterans With PTSD | MDMA | Phase 1 / Phase 2 | Completed | Portland VA Research Foundation, Inc | PTSD | Oct 1, 2023 |
| Northwest Therapies Trauma Psilocybin Study Compassionate Use Study | Psilocybin | Phase 1 | Unknown | NWTraumatherapies | Trauma, Nervous System | Sep 3, 2023 |
| Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder | Psilocybin | Phase 2 | Active Not Recruiting | Ohio State University | PTSD, Stress Disorders, Traumatic, Stress Disorders, Post-Traumatic, Trauma and Stressor Related Disorders, Mental Disorder | Jan 1, 2023 |
| Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD | MDMA | N/A | Completed | Albany Research Institute, Inc. | Post Traumatic Stress Disorder | Aug 8, 2022 |
| Trifecta Research Study | Multiple | N/A | Active Not Recruiting | Axial Therapeutic Research | PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Injury, Depression - Major Depressive Disorder, Suicidal Ideation | Aug 1, 2022 |
| The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | Psilocybin | Phase 2 | Completed | COMPASS Pathways | Post Traumatic Stress Disorder | Jun 10, 2022 |
| Frontline Clinician Psilocybin Study | Psilocybin | Phase 3 | Completed | University of Washington | Burnout, Caregiver, Burnout, Professional, COVID-19, Depression, Post Traumatic Stress Disorder, Moral Injury | Mar 3, 2022 |
| Sustaining Remission From PTSD Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy | MDMA | N/A | Unknown | Apollo Neuroscience, Inc. | Stress Disorders, Post-Traumatic | Dec 8, 2021 |
| Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure | Ibogaine | N/A | Active Not Recruiting | Stanford University | Blast or Combat Exposure, Head Injury Trauma | Nov 15, 2021 |
| Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD | MDMA | Phase 2 | Terminated | Resilient Pharmaceuticals | PTSD | Nov 8, 2021 |
| MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD | MDMA | Phase 2 | Completed | VA Loma Linda Health Care System | Post Traumatic Stress Disorder, Combat Stress Disorders | Jul 29, 2021 |
| A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD | MDMA | Phase 3 | Completed | Resilient Pharmaceuticals | PTSD | Mar 8, 2021 |
| Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD | MDMA | N/A | Completed | Resilient Pharmaceuticals | PTSD | Mar 1, 2021 |
| A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2) | MDMA | Phase 3 | Completed | Resilient Pharmaceuticals | Posttraumatic Stress Disorder | Sep 2, 2020 |
| A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health | Psilocybin | Phase 4 | Completed | Field Trip Health | Depression, Anxiety, Post Traumatic Stress Disorder | Mar 13, 2020 |
| Effects of Psilocybin in Concussion Headache | Psilocybin | Phase 1 | Terminated | Yale University | Post-Traumatic Headache | Mar 28, 2019 |
| A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1) | MDMA | Phase 3 | Completed | Resilient Pharmaceuticals | Posttraumatic Stress Disorder | Nov 21, 2018 |
| Epigenetics and MDMA-Assisted Psychotherapy for PTSD | MDMA | Phase 3 | Completed | University of Southern California | PTSD | Nov 20, 2018 |
| Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD | MDMA | Phase 2 | Completed | Resilient Pharmaceuticals | PTSD | Nov 16, 2017 |
| Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD | Psilocybin | Phase 2 | Completed | Multidisciplinary Association for Psychedelic Studies | Posttraumatic Stress Disorder | Jan 2, 2017 |
| MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD | MDMA | Phase 1 / Phase 2 | Completed | Resilient Pharmaceuticals | Posttraumatic Stress Disorder | Jul 3, 2016 |
| Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD | MDMA | N/A | Completed | Resilient Pharmaceuticals | Posttraumatic Stress Disorder | Jan 1, 2014 |
| Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD | MDMA | Phase 2 | Completed | Resilient Pharmaceuticals | Posttraumatic Stress Disorder | May 13, 2013 |
| Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial | MDMA | Phase 2 | Completed | Resilient Pharmaceuticals | Posttraumatic Stress Disorder | Dec 15, 2010 |
| Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder | MDMA | Phase 2 | Completed | Resilient Pharmaceuticals | Posttraumatic Stress Disorder | Nov 10, 2010 |
| MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder | MDMA | Phase 2 | Completed | Resilient Pharmaceuticals | Posttraumatic Stress Disorder | Mar 12, 2004 |
| A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD | MDMA | N/A | No Longer Available | Resilient Pharmaceuticals | Post Traumatic Stress Disorder |
Psychedelic Clinical Trials for Depression · Psychedelic Clinical Trials for Addiction · Psychedelic Clinical Trials for Anxiety · All psychedelic clinical trials
No. MDMA remains a Schedule I substance and is not FDA approved. It is available only through authorized clinical trials or expanded access programs, despite completed Phase III studies.
Psilocybin and ibogaine are both being investigated for trauma-related symptoms, particularly in veterans. Some programs combine ibogaine with 5-MeO-DMT in observational settings outside the U.S.
Yes. Several sponsors run programs specifically enrolling veterans and active-duty service members. Check each ClinicalTrials.gov record for its eligibility criteria and site list.
Participants attend a small number of supervised dosing sessions, each lasting several hours, bracketed by preparatory and integration psychotherapy sessions with trained therapists.
Open a listing to view its ClinicalTrials.gov record, which lists every study location with its recruitment status and contact information.